Medigen Vaccine, Dynavax begin phase II trial for subunit COVID-19 vaccine

By The Science Advisory Board staff writers

January 25, 2021 -- Medigen Vaccine Biologics and Dynavax Technologies have dosed the first participant in a phase II clinical trial evaluating Medigen's COVID-19 vaccine candidate, MVC-COV1901, a subunit vaccine with a recombinant spike-2P antigen adjuvanted with Dynavax's CpG 1018.

The spike-2P antigen is a trimeric and prefusion stable recombinant protein developed by the U.S. National Institutes of Health (NIH). Medigen has obtained the global technology license for spike-2P from the U.S. Vaccine Research Center at NIH. The new study is based on positive phase I interim data demonstrating a good safety profile and encouraging immunogenicity of the vaccine candidate.

The phase II trial, located in Taiwan, is a randomized, double-blinded, multicenter trial expected to enroll 3,700 healthy subjects, 20 years of age and older. It will evaluate safety and immunogenicity with a dosing regiment of two intramuscularly administered doses one month apart.

Dynavax partners on Valneva's SARS-CoV-2 vaccine candidate
Dynavax will supply its CpG 1018 adjuvant for use in Valneva's SARS-CoV-2 vaccine candidate, VLA2001, as part of a commercial partnership.
COVID-19 vaccine candidates show progress amid challenges
As the COVID-19 outbreak advances worldwide, companies are stepping up to the challenge to develop a potential vaccine. There are over 75 confirmed COVID-19...
Dynavax, Clover partner for protein-based COVID-19 vaccine
A new research collaboration between Dynavax Technologies and Clover Biopharmaceuticals aims to develop a vaccine candidate to prevent COVID-19. The partnership,...

Copyright © 2021

Register below for our weekly Letter from the Editor to receive the latest Science news and insights.
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter